Entasis Therapeutics

Entasis Therapeutics
Boston, USA
Current Development Stage
REPAIR Impact Fund Investment
USD 10m in the Initial Public Offering to support the NBP program
Company Website

Addressing the urgent need of gram-negative multi-drug resistant bacteria

Entasis Therapeutics is developing a portfolio of innovative product candidates to treat serious Gram-negative multi-drug resistant bacterial infections.  Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), ETX0282CPDP (targeting Enterobacteriaceae infections), and Non-Beta-lactam PBP inhibitors or NBPs (targeting Gram-negative infections).

 Repair uses cookies to ensure that we give you the best experience on our website. Read more